Funder
The study was funded by an unrestricted investigator initiated grant by InterMune/Roche
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference16 articles.
1. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The voice of the patient; a series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. Idiopathic Pulmonary Fibrosis. March 2015. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM440829.pdf Date last updated: March 2015. Date last accessed: January 2017.
2. Objective cough frequency in Idiopathic Pulmonary Fibrosis
3. Cough predicts prognosis in idiopathic pulmonary fibrosis
4. A Study of the Cough Reflex in Idiopathic Pulmonary Fibrosis
5. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献